UBS initiated coverage of Alkermes with a Neutral rating and $31 price target. While Alkermes’ antipsychotic Lybalvi has had a strong successful early launch and the stock is up 25% over the last year, UBS struggles to see much upside or downside to Lybalvi consensus expectations going forward, the analyst tells investors in a research note. Additionally, the firm believes the upcoming Phase 1b data at World Sleep is unlikely to be a big reveal, and questions the long-term commercial opportunity for orexins, given sodium oxybate is likely to remain backbone therapy, plus narcolepsy pricing may collapse post-2026.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALKS:
- Mizuho expects ‘promising’ early data from Alkermes at World Sleep
- Alkermes gets few more years of Vivitrol exclusivity, says Piper Sandler
- Mizuho says Vivitrol patent settlement removes ‘key overhang’ for Alkermes
- Alkermes reaches settlement with Teva regarding VIVITROL patent litigation
- Jefferies reiterates Buy rating on Alkermes ahead of World Sleep meeting